Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update.

In the case of pembrolizumab, the study from Le and colleagues [ 12 ] showed that a high number of mutations was associated with a longer PFS, while the presence of CD8+ lymphocytes and expression of PD-L1 showed a trend toward objective response, although differences in PFS and OS were not statistically significant.

also in 53,322 other papers